GEA
RARE icon

Glen Eagle Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Glen Eagle Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-60
Closed -$4.58K – 738
2018
Q3 		$4.58K Hold
60
– – ﹤0.01% 573
2018
Q2 		$4.61K Buy
+60
New +$3.88K ﹤0.01% 549

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Glen Eagle Advisors's RARE Position: Q4 2018 in Review

Glen Eagle Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2018, closing a stake of 60 shares — an estimated $4.58K sold.

Glen Eagle Advisors first reported a position in RARE in Q2 2018 and held it in 2 quarters. The position peaked at $4.61K in Q2 2018. 164 funds tracked by Wall St. Rank hold RARE as of Q4 2018.

  • Glen Eagle Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q4 2018 after selling out during the quarter.
  • Glen Eagle Advisors sold 60 Ultragenyx Pharmaceutical shares in Q4 2018, an estimated $4.58K.
  • Glen Eagle Advisors first reported a position in Ultragenyx Pharmaceutical in Q2 2018 and held it in 2 quarters.
  • Glen Eagle Advisors's Ultragenyx Pharmaceutical position peaked at $4.61K in Q2 2018.
  • 164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2018.

Based on Glen Eagle Advisors's 13F filing for Q4 2018, filed 13 Aug 2024.